Quick Summary:
In an ever-evolving pharmaceutical industry, being informed of the latest trends and developments is paramount. The global market for Myelodysplastic Syndrome (MDS) Drugs, due to escalate in value to an estimated US$4.1 Billion by 2030, represents a significant realm of opportunity for pharmaceutical developers, healthcare investors, and industry stakeholders to capitalize.
Stay ahead of the curve with our comprehensive MDS Drugs market research report. Besides quantitative data on the market’s robust growth, the report offers detailed analysis of key market segments like Immunomodulatory Drugs and Hypomethylating Agents, their projected growth rates, and their contribution to the market's overall value. It provides a penetrating look into frequently under-explored yet powerful markets like China and internationally recognized leaders such as the U.S., Germany, Japan, and Canada. With detailed profiling and analysis of select competitors, this report equips you with an invaluable competitive edge and comprehensive understanding of the MDS Drugs global marketplace.
Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $4.1 Billion by 2030
The global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$4.1 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2022-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is projected to record 10.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hypomethylating Agents segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $510.7 Million, While China is Forecast to Grow at 16.7% CAGR
The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$510.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 16.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 8.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.Select Competitors (Total 34 Featured) -
- Amgen
- BluePoint Laboratories
- Celgene Corporation
- Celgene Europe Limited
- Johnson & Johnson
- Lupin Ltd Corporation
- Otsuka America Pharmaceutical Inc.
- Reddy's Laboratories, Inc.
- Sandoz
- Shilpa Medicare Limited
- Sun Pharmaceutical Industries Inc.
- Takeda
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Myelodysplastic Syndrome (MDS) Drugs?
What is the growth rate of the Global Market for Myelodysplastic Syndrome (MDS) Drugs?
What is the forecasted size of the Global Market for Myelodysplastic Syndrome (MDS) Drugs?
Who are the key companies in the Global Market for Myelodysplastic Syndrome (MDS) Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1.9 Billion |
| Forecasted Market Value ( USD | $ 4.1 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amgen
- BluePoint Laboratories
- Celgene Corporation
- Celgene Europe Limited
- Johnson & Johnson
- Lupin Ltd Corporation
- Otsuka America Pharmaceutical Inc.
- Reddy's Laboratories, Inc.
- Sandoz
- Shilpa Medicare Limited
- Sun Pharmaceutical Industries Inc.
- Takeda
